Cellviewimaging
75,287 employees on LinkedIn · 1 known investors
Cellview develops the WRI-1, a widefield non-mydriatic retinal imaging device that captures up to 133° in a single image and auto-stitches up to 200° for retinal periphery screening. The system is designed for eye care professionals to image patients including those with small pupils, cataracts, or other media opacities.
Also known as Cellview · Cellview Imaging · WRI-1
Investors · 1
Company profile
researched Aug 2026Cellview is a retinal imaging product line, presented on its website under the Essilor Instruments brand, whose product is the WRI-1 widefield non-mydriatic retinal imager. The device captures up to 133° of the retina in a single image and produces auto-stitched visualizations of up to 200°, extending the field of view beyond standard fundus cameras so that clinicians can screen the retinal periphery for abnormalities. Imaging is possible through pupils as small as 2.5 mm, removing the need for pharmacological dilation, and a low-intensity illumination system is used for patient comfort.
The system uses a full visible spectrum four-LED array for full-color retinal images, combined with digital filters that provide multiple visualization modes for image review. Automated capture features — auto-focus and auto-gain — reduce manual adjustment, with auto gain control intended to keep image output balanced across different levels of retinal pigmentation. The company positions the device as easy to operate by minimally trained operators, with a short learning curve and low dependence on operator variability.
Connectivity features include encrypted cloud-based storage and access to patient images and data, a Remote Review Station and Web Review for remote patient assessment and collaboration between eye care professionals, an auto-export function after each acquisition, DICOM support for integration with compatible EMR and PACS systems, and a remote service feature (availability varying by market) intended to reduce reliance on onsite technicians and limit downtime.
▸Full profile — market position, technology, go-to-market, geography
Market position
Cellview positions the WRI-1 against traditional fundus cameras by offering a wider field of view (up to 200° auto-stitched) and non-mydriatic operation. The website presents the product within the Essilor Instruments portfolio, alongside other categories including screening and diagnostics, refraction, optical workshop and digital fitting.
Technology
The WRI-1 performs widefield non-mydriatic retinal imaging, capturing up to 133° in a single shot and auto-stitching to up to 200°. It images through pupils as small as 2.5 mm using a low-intensity illumination system, and uses a four-LED array covering the full visible spectrum for full-color imaging, with digital filters enabling multiple visualization modes. Automated auto-focus and auto-gain functions, including auto gain control that balances output across retinal pigmentation levels, support consistent image quality. Data handling includes encrypted cloud transfer and storage, auto-export after acquisition, DICOM connectivity to compatible EMR and PACS systems, and remote review via a Remote Review Station and Web Review; a remote service capability supports software updates and servicing without onsite technicians.
Go-to-market
The product is marketed through the Essilor Instruments-branded website with a downloadable brochure, contact and events pages, and local sales teams; certain features, such as remote service, are available depending on the market.
Eye care professionals and clinical practices performing retinal screening and evaluation, including high-volume workflows and settings with minimally trained operators. The device is aimed at imaging patients traditionally difficult to image, such as those with small pupils, cataracts or other media opacities, and supports referral of patients with retinal abnormalities to specialized eye care providers.
Geography
Availability of some features, including the remote service capability, varies by market, with reference to local sales teams.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 1
primary sources listed
- Cellviewimagingcellviewimaging.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Cellviewimaging do?
- Cellview makes the WRI-1, a non-mydriatic widefield retinal imager capturing up to 133° per image and 200° auto-stitched.
- Who are Cellviewimaging's investors?
- Cellviewimaging's investors include Evolution VC Partners.